Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

Initiation of adjuvant chemotherapy and trastuzumab for human epidermal growth receptor 2-positive early invasive breast cancer in a population-based cohort study of older women in England

DODWELL D., (2020), Journal of Geriatric Oncology

Addressing frailty in patients with breast cancer: A review of the literature

Jauhari Y. et al, (2020), European Journal of Surgical Oncology, 46, 24 - 32

Immediate and delayed autologous abdominal microvascular flap breast reconstruction in patients receiving adjuvant, neoadjuvant or no radiotherapy: a meta‐analysis of clinical and quality‐of‐life outcomes

Khajuria A. et al, (2019), BJS Open

Eligibility for Partial Breast Radiotherapy in England.

Taylor CW. et al, (2019), Clin Oncol (R Coll Radiol)

Endocrine therapy in the years following a diagnosis of breast cancer: A proof of concept study using the primary care prescription database linked to cancer registration data.

Emanuel G. et al, (2019), Cancer Epidemiol, 61, 185 - 189

International Variation in Criteria for Internal Mammary Chain Radiotherapy.

Duane FK. et al, (2019), Clin Oncol (R Coll Radiol)

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2019), Lancet, 393, 1440 - 1452

Adjuvant treatment for breast cancer

Flatley MJ. and Dodwell DJ., (2019), Surgery (United Kingdom)

The SMALL Trial: A Big Change for Small Breast Cancers

Morgan J. et al, (2019), Clinical Oncology

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM. et al, (2018), Eur J Cancer, 101, 210 - 219

Should patients with ductal carcinoma in situ be treated with adjuvant whole breast radiotherapy after breast conservation surgery?

Bagenal J. et al, (2018), BMJ, 361

Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ.

Maxwell AJ. et al, (2018), Eur J Surg Oncol, 44, 429 - 435

Neoadjuvant chemotherapy for early breast cancer - Author's reply.

McGale P. et al, (2018), Lancet Oncol, 19

A longitudinal cohort study to identify risk factors for the development of invasive cancer in unresected DCIS

Maxwell AJ. et al, (2018), CANCER RESEARCH, 78

Impact of radiotherapy and endocrine therapy on further events: Final multivariate analysis of a prospective, national cohort study of screen detected ductal carcinoma in situ (DCIS) of the breast

Thompson AM. et al, (2018), CANCER RESEARCH, 78

Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG) None., (2018), Lancet Oncol, 19, 27 - 39

Making progress in early breast cancer: Taking time or accepting risk?

Mannu GS. and Dodwell D., (2017), Eur J Cancer, 78, 24 - 27

Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.

Taylor C. et al, (2017), J Clin Oncol, 35, 1641 - 1649

Doing More With Less; Are There Some ‘Easy Wins’ in the Management of Early Breast Cancer?

Dodwell DJ. et al, (2017), Clinical Oncology

30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.

Wallington M. et al, (2016), Lancet Oncol, 17, 1203 - 1216

Load More

Include forthcoming?